Aminocaproic Acid Suppliers & Bulk Manufacturers
Available Forms: Tablet/ Oral Solution/ Injection
Available Strengths: 500mg, 250 mg/mL
Reference Brands: Amicar (USA), Acepramin (EU)
Category:
Critical Care
Aminocaproic acid is an antifibrinolytic agent that helps prevent or reduce excessive bleeding by inhibiting the breakdown of blood clots. It is used in conditions such as surgery, trauma, or bleeding disorders to stabilize clots and control hemorrhage. The drug is available in oral tablets, oral solution, and injectable forms, and is typically used under medical supervision in critical care or surgical settings.
Aminocaproic Acid is available in Tablet/ Oral Solution/ Injection
and strengths such as 500mg, 250 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aminocaproic Acid is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aminocaproic Acid can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing